Text
In the past 20 years, some nanomedicines have been approved, yet their transition from lab to treatment has been slow. Many face safety issues post-approval, leading to withdrawal. Our research explores nanoparticle-induced lysosomal disruption, revealing size and composition influence cellular interactions, elimination, and toxicity. We've identified lysosome dysregulation as the primary nanotoxicity cause and emphasized the need to consider nanoparticles individually due to their unique properties.
Description
Schematic cellular mechanism of lysosomal nanotoxicity triggered by administered nanomedicines. Created with BioRender.com.